Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
The dense collagen network in tumors significantly reduces the penetration and efficacy of nanotherapeutics. We tested whether losartan-a clinically approved angiotensin II receptor antagonist with noted antifibrotic activity-can enhance the penetration and efficacy of nanomedicine. We found that lo...
Main Authors: | Diop-Frimpong, Benjamin (Contributor), Chauhan, Vikash P. (Author), Krane, Stephen (Author), Boucher, Yves (Author), Jain, Rakesh K. (Author) |
---|---|
Other Authors: | Harvard University- (Contributor) |
Format: | Article |
Language: | English |
Published: |
National Academy of Sciences (U.S.),
2011-09-23T18:46:47Z.
|
Subjects: | |
Online Access: | Get fulltext |
Similar Items
-
Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.
by: Peng Jiang, et al.
Published: (2015-01-01) -
Tumor Site-Dependent Transport Properties Determine Nanotherapeutics Delivery and Its Efficacy
by: Megumi Kai, et al.
Published: (2019-09-01) -
Nanotherapeutics in angiogenesis: synthesis and in vivo assessment of drug efficacy and biocompatibility in zebrafish embryos
by: Cheng J, et al.
Published: (2011-09-01) -
Targeted nanotherapeutics in cancer
by: Shiekh FA
Published: (2014-03-01) -
Quantitative imaging of intracellular nanoparticle exposure enables prediction of nanotherapeutic efficacy
by: Qingqing Yin, et al.
Published: (2021-04-01)